After Alzheimer's trial woes, Biogen's R&D chief quits to he...

Michael Ehlers is to quit as head of Biogen’s troubled R&D outfit, taking a role as chief executive of New York-based venture capitalist Apple Tree Partners.

Last BACE bombs: Eisai, Biogen give up on elenbecestat

Who will be the biggest pharma players in orphan drugs?

New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Roche coming out in the lead.

Novartis strikes marketing deal for Polpharma's potential Ty...

Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab).<

Under threat from Novartis, Biogen hails new data from SMA d...

Under threat from a gene therapy from Novartis, Biogen is making the case for its drug Spinraza for the muscle wasting disease spinal muscular atrophy, with new data that it hopes persuades

AbbVie makes case for Humira follow-on upadacitinib at EULAR

The summer medical conference season is well and truly upon us and much of the focus this week is on the European League Against Rheumatism (EULAR) conference where several big pharma compa